Medicortex Finland has announced the start of a clinical trial for detection of mild Traumatic Brain Injury (TBI) and concussion.
The clinical trial will be conducted at Satasairaala hospital in Pori – the main hospital in Satakunta region with the first level pediatric emergency department and expertise in the TBI management. Body fluid samples will be collected from young patients (0 – 17 years) with suspected mild TBI, and the samples will be studied with respect to a specific biomarker signature following a head injury. The Principal Investigator, Dr. Sari Malmi, Head of the Department of Pediatric Surgery, says that a new test for improving the diagnosis of traumatic brain injury is highly needed. It will improve the examination of young patients with a traumatic brain injury and thus improve the quality of their treatment, states the company.
Children in particular will benefit
“ProbTBITM will be a highly innovative diagnostic kit for rapid detection of concussion. Children in particular will benefit from it since they can be refrained from radiation or sedation which are needed for the CT scan of the head, as well as from an exposure to other sick patients in the hospital,” says Dr. Adrian Harel, CEO of Medicortex. “Participation of the young patients shortly after a head injury will be a challenge, but we have a committed and skilled clinical team working for us in the hospital.”
In this clinical trial, Medicortex seeks to collect a sufficient number of pediatric samples in order to prove the applicability of the brain injury test in children, as a natural continuation for previously proven clinical performance in adults.